Sign in

Research summary ·

Recommendations of the German, Austrian and Swiss rheumatology and other medical societies for the management of polymyalgia rheumatica.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This is a guideline on how doctors treat polymyalgia rheumatica, or PMR. PMR is an inflammatory disease seen in older adults. Groups from Germany, Austria and Switzerland first wrote this guideline in 2018. Now they have updated it. They searched for studies from July 2016 to January 2024. These studies looked at treatments and at signs of how the disease goes. A team of 12 doctors, other health workers and patients wrote the update. They used the studies plus their own expert views.

What they found

The guideline again says doctors start with glucocorticoids once PMR is confirmed. The start dose is 15-25 mg of prednisone, or a like dose, each day. Doctors then lower the dose slowly over 4-12 months. How fast depends on whether a drug is used to spare glucocorticoids. Doctors also check disease activity and harms from treatment. Some people have disease that comes back. For them, the guideline says doctors should think about adding an interleukin-6 receptor blocker. Some people have new PMR and a high risk of glucocorticoid harms. For them, doctors can think about these drugs too. Methotrexate or rituximab may be other choices. Frail and older people should also be offered an exercise plan. The plan should be made for each person.

What it means for patients

The authors say the update aims to help doctors make choices based on evidence. They want good care for all people with PMR. It sets out the steps the guideline gives doctors. These include glucocorticoids first, with other drugs in some cases.

Why it is not certain yet

The abstract does not say how strong the evidence was for each point. Some advice rests on expert views, not only on studies. The abstract does not list the studies found or their results. A guideline can only be as good as the studies behind it.

Source

Recommendations of the German, Austrian and Swiss rheumatology and other medical societies for the management of polymyalgia rheumatica.

PubMed · PMID 41346249

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Polymyalgia rheumatica publications